These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38697872)

  • 21. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel therapeutic approaches in polycythemia vera.
    Foucar CE; Stein BL
    Clin Adv Hematol Oncol; 2018 Nov; 16(11):750-757. PubMed ID: 30543590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
    Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.
    Palandri F; Branzanti F; Venturi M; Dedola A; Fontana G; Loffredo M; Patuelli A; Ottaviani E; Bersani M; Reta M; Addimanda O; Vicennati V; Vianelli N; Cavo M
    Ann Hematol; 2024 Jul; 103(7):2347-2354. PubMed ID: 38771499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
    Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R
    Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interferon therapy for chronic hepatitis B].
    Hige S; Sho T; Nakanishi M; Chuma M
    Nihon Rinsho; 2011 May; 69 Suppl 4():481-5. PubMed ID: 22096965
    [No Abstract]   [Full Text] [Related]  

  • 27. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
    Pedersen RK; Andersen M; Knudsen TA; Sajid Z; Gudmand-Hoeyer J; Dam MJB; Skov V; Kjaer L; Ellervik C; Larsen TS; Hansen D; Pallisgaard N; Hasselbalch HC; Ottesen JT
    Cancer Med; 2020 Mar; 9(6):2039-2051. PubMed ID: 31991066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].
    Wu CH; Wang LF; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):873. PubMed ID: 21138646
    [No Abstract]   [Full Text] [Related]  

  • 29. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E
    Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
    [No Abstract]   [Full Text] [Related]  

  • 30. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron
    Green DS; Nunes AT; David-Ocampo V; Ekwede IB; Houston ND; Highfill SL; Khuu H; Stroncek DF; Steinberg SM; Zoon KC; Annunziata CM
    J Transl Med; 2018 Jul; 16(1):196. PubMed ID: 30012146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon alfa-2b combined with tenofovir disoproxil fumarate induced high clinical cure rate in inactive chronic hepatitis B virus carriers.
    Chen XB; Liu FF; Shu FL; Liu JY; Yang JH
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101723. PubMed ID: 34091082
    [No Abstract]   [Full Text] [Related]  

  • 33. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
    Tan SS; Adlin Nadia Z
    Med J Malaysia; 2017 Jun; 72(3):165-174. PubMed ID: 28733564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children and Adolescents: A Systematic Review and Meta-analysis.
    He Y; Yin J; Xu H
    Pediatr Infect Dis J; 2020 Dec; 39(12):1121-1126. PubMed ID: 32858647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
    Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
    Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera.
    Ishii T; Xu M; Zhao Y; Hu WY; Ciurea S; Bruno E; Hoffman R
    Leukemia; 2007 Feb; 21(2):373-4. PubMed ID: 17122864
    [No Abstract]   [Full Text] [Related]  

  • 39. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
    Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL
    J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential Therapy with PEG-IFN alpha-2a and Tenofovir in a Hepatitis B Virus-Infected African Man.
    Cainelli F; Vento S
    Isr Med Assoc J; 2015 Dec; 17(12):790. PubMed ID: 26897988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.